טוען...
LAG3 (CD223) as a Cancer Immunotherapy Target
Despite the impressive impact of CTLA4 and PD1-PDL1 targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironmen...
שמור ב:
| הוצא לאור ב: | Immunol Rev |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5338468/ https://ncbi.nlm.nih.gov/pubmed/28258692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12519 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|